141 related articles for article (PubMed ID: 12719085)
1. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
Herndon LW; Robert D Williams ; Wand M; Asrani S
Am J Ophthalmol; 2003 May; 135(5):713-5. PubMed ID: 12719085
[TBL] [Abstract][Full Text] [Related]
2. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
Sodhi PK; Verma L; Ratan SK
Am J Ophthalmol; 2004 Apr; 137(4):783. PubMed ID: 15059736
[No Abstract] [Full Text] [Related]
3. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
[TBL] [Abstract][Full Text] [Related]
4. Adverse periocular reactions to five types of prostaglandin analogs.
Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
[TBL] [Abstract][Full Text] [Related]
5. Increased eyelid pigmentation associated with use of latanoprost.
Kook MS; Lee K
Am J Ophthalmol; 2000 Jun; 129(6):804-6. PubMed ID: 10926995
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of bimatoprost-induced periocular skin changes in Caucasians.
Doshi M; Edward DP; Osmanovic S
Ophthalmology; 2006 Nov; 113(11):1961-7. PubMed ID: 16935336
[TBL] [Abstract][Full Text] [Related]
7. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
[TBL] [Abstract][Full Text] [Related]
8. Periocular changes in topical bimatoprost and latanoprost use.
Karslioğlu MZ; Hoşal MB; Tekeli O
Turk J Med Sci; 2015; 45(4):925-30. PubMed ID: 26422869
[TBL] [Abstract][Full Text] [Related]
9. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
10. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.
Manni G; Centofanti M; Parravano M; Oddone F; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):767-70. PubMed ID: 15241611
[TBL] [Abstract][Full Text] [Related]
11. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
12. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.
Aihara M; Shirato S; Sakata R
Jpn J Ophthalmol; 2011 Nov; 55(6):600-4. PubMed ID: 21953485
[TBL] [Abstract][Full Text] [Related]
13. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
[TBL] [Abstract][Full Text] [Related]
14. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma.
Dirks MS; Noecker RJ; Earl M; Roh S; Silverstein SM; Williams RD
Adv Ther; 2006; 23(3):385-94. PubMed ID: 16912020
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
[TBL] [Abstract][Full Text] [Related]
16. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
Inoue K; Shiokawa M; Wakakura M; Tomita G
J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
[TBL] [Abstract][Full Text] [Related]
17. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
18. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
Law SK; Song BJ; Fang E; Caprioli J
Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
[TBL] [Abstract][Full Text] [Related]
20. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
